KRT88P and hematologic disorder: The present randomized study (PREBLIN) aimed to compare the efficacy of TDF prophylaxis vs no therapy in the prevention of HBV reactivation in anti-HBc-positive, HBsAg-negative patients treated with RTX for hematologic malignancy.